Clinical Context
A typical patient is an adult with relapsed or refractory multiple myeloma who is a candidate for immunotherapy with elotuzumab. The patient presents to an outpatient infusion center or hospital outpatient department for intravenous administration of J9176 (elotuzumab) dosed per provider orders. Prior to infusion, oncology nursing performs medication verification, allergy check, baseline vital signs, and premedication orders (antipyretic, antihistamine, corticosteroid) as indicated. An indwelling peripheral IV or central venous access device is used depending on venous access and therapy plan. The infusion is administered by an oncology-certified infusion nurse with monitoring for infusion reactions; vital signs are recorded at baseline, periodically during infusion, and post-infusion. The encounter includes documentation of diagnosis(es) justifying therapy, medication lot and NDC verification, infusion start/stop times, any reactions and interventions, and instructions for follow-up oncology visits and laboratory monitoring (CBC, CMP). Typical sites of service are outpatient oncology infusion centers, hospital outpatient departments, and occasionally skilled nursing facilities with appropriate oncology infusion capabilities.